GC Aesthetics Announces Growth and Expansion in Brazil

GC Aesthetics (GCA), a privately-held medical technology company providing Women Healthcare Aesthetic and Reconstructive Solutions, has announced today, its growth and expansion plans for the Brazilian market, the second largest Breast Augmentation market in the world.

GC Aesthetics has been executing an ambitious journey repositioning the brand and portfolio to offer a smart, unique, and clinically proven safe range of products to meet the needs of Brazilian women and surgeons.

The Brazilian growth strategy includes 2 main pillars. First, the commercialization of all GC Aesthetics® products and solutions designed to support the best outcome for women’s breast enhancement journey, before, during and after surgery. This unique portfolio not only stands out in today’s industry but is aligned with the company leadership position and growing plans evolving from Breast Implant Manufacturers to Solution Providers.

The Brazilian revenue growth of GC Aesthetics® is also linked to the ANVISA certificate (Brazilian Health Regulatory Agency) just obtained for the re-introduction of The Round Collection™ Breast Implants. This unique microtextured surface breast implant has been the preferred option by surgeons in Brazil: 99% of surveyed Plastic Surgeons consider The Round Collection™ as the trustable product in terms of safety and performance.

“According to our most recent survey, long-term proven safety & the unique type of micro texture are the 2 top reasons Brazilian Plastic Surgeons prefer The Round Collection Implants against competitors. We are beyond excited to be back in Brazil with this product and offer Surgeons and Patients, a proven long-term, safe and reliable medical device. Pre-orders of this product have exceeded what we had planned, and we are looking forward to a very bright, leading future in Brazil and in the world” – said Carlos Reis Pinto, CEO of GC Aesthetics®

“At GCA®, we are dedicated to advancing the science of medical aesthetics and delivering exceptional clinical, operational and commercial performance to be the preferred partner of surgeons and physicians worldwide, we are excited for The Round Collection™ re-entry in Brazil and are excited of presenting our brand as ONE GCA” – mentioned Ron Cosmas, CCO of GCA®.

GC Aesthetics® will be presenting the re-introduction of this product at the Jornada Paulista de Cirurgia Plástica, held from June 15th to the 18th at the WTC São Paulo, Brazil. Engineered and designed for performance The Round Collection™ breast implants have an unparalled long-term safety profile. The Round Collection™ by GC Aesthetics® is part of the largest European long-term clinical study for breast implants with exceptional results at 10 years and recently had data published in a one-of-a-kind 17 year patient follow-up with remarkable patient satisfaction.

GC Aesthetics is a long-established global medical technology company that develops, manufactures and markets a comprehensive range of proprietary aesthetic products that empower patients to feel confident and secure in their personal life journey.

Throughout its 40-year history, GCA has been dedicated to advancing the science of medical aesthetics and delivering high-quality breast implants for breast augmentation and breast reconstructive surgery. We have sold more than 3 million implants across 70 countries, and our products are supported by published 10-year clinical data demonstrating compelling safety and clinical effectiveness.

The company’s vertically integrated strategy enables exceptional clinical, operational and commercial performance, which allows GCA to provide competitively differentiated products to surgeons and patients. Through a culture of continuous innovation and dedication to customer-responsiveness, GCA has established itself as a leading provider of medical aesthetics solutions and the partner-of-choice for patients seeking to improve their lives.

 

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version